Amersham WB automated Western blot

One Bench at a Time

Amersham WB automated Western blot

Fully integrated system for SDS-PAGE and Western blotting of proteins based on fluorescence detection.

  • Integrated Western blotting system with standardized protocols in every step minimizes assay variability.
  • Dedicated consumables and reagents ensure high quality and reproducibility.
  • Optimized prelabeling of samples with Cy5 NHS chemistry for proven performance, eliminating the need for gel staining.
  • Reliable normalization by multiplexing target and control fluorescent signals on the same blot.
  • Western blot workflow achieved in less than 4 h ensures fast, conclusive data.
  • Smart control and evaluation software gives you complete control.

The Amersham WB system consists of the Amersham WB analyzer, Amersham WB software, and dedicated consumables for electrophoresis and Western blotting.

Amersham WB Analyzer

The Amersham WB analyzer is divided into two instrument units—one for electrophoresis and scanning and one for the full Western blot workflow including transfer, probing, and drying. The electrophoresis & scanning unit is used to separate SDS-treated sample proteins in a polyacrylamide gel. It is also used to scan gels after electrophoresis and scan polyvinylidene (PVDF) cards after probing and drying in a Western experiment.

The Western unit is used to:

    • (1) transfer separated proteins in the gel to the PVDF membrane;
    • (2) probe proteins on the membrane with primary antibodies and secondary antibodies conjugated to a CyDye;
    • (3) dry the PVDF cards (before scanning in the electrophoresis & scanning unit).

The Amersham WB system provides standardized, quantitative, and reproducible analysis of proteins in your samples in a significantly shorter time compared with traditional workflows/procedures.

Learn more at GE Healthcare

Upcoming Event

  • Reaction before action: new approaches to biomineralization-associated diseases

    12:30-13:30
    10/19/2017
    Daniel Laser, PhD CEO and Co-Founder, Applaud Medical RSVP Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category. About Daniel Laser Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter